- Zacks•8 days ago
VIVUS, Inc. (VVUS) acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.
- Marketwired•10 days agoVIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
VIVUS, Inc. and Selten Pharma, Inc., announced VIVUS' acquisition from Selten of exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary ...
- Investopedia•13 days ago
Arena transferred the rights to its weight loss drug Belviq to its Japanese partner Eisai.
VVUS: Summary for VIVUS, Inc. - Yahoo Finance
VIVUS, Inc. (VVUS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
|Bid||1.13 x 300|
|Ask||2.59 x 100|
|Day's range||1.15 - 1.19|
|52-week range||0.92 - 1.85|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-2.66|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|